Paige Fletcher1, Raymond F Hamilton2, Joseph F Rhoderick2, Britten Postma2, Mary Buford2, James J Pestka3, Andrij Holian2. 1. Department of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA. paige.fletcher@umontana.edu. 2. Department of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, 32 Campus Drive, Missoula, MT, 59812, USA. 3. Department of Food Science and Human Nutrition, Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.
Abstract
OBJECTIVE AND DESIGN: The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has been reported to suppress inflammation. Pulmonary inflammation can be directly linked to exposure of various occupational and man-made particles leading to pulmonary diseases. Therapeutic treatments are lacking for particle-induced pulmonary inflammation. These studies evaluated DHA as a therapeutic treatment for semi-acute and chronic particle-induced pulmonary inflammation. METHODS: Balb/c mice were oropharyngeal instilled with hydrophobic multi-walled carbon nanotube (MWCNT) or hydrophilic crystalline silica (SiO2) either as one instillation (semi-acute) or once a week for 4 weeks (chronic). One week later, the mice were placed on either a control or 1% DHA-containing diet for 3 weeks (semi-acute) or 12 weeks (chronic). Mice were assessed for inflammatory signaling within the lung lavage fluid, impact on phagolysosomal membrane permeability, shifts of macrophage phenotype gene expression (M1, M2a, M2b, and M2c), and pulmonary histopathology. RESULTS: DHA increased pulmonary inflammatory markers and lung pathology when mice were exposed to SiO2. There were trending decreases of inflammatory markers for MWCNT-exposed mice with DHA treatment, however, mostly not statistically significant. CONCLUSION: The anti-inflammatory benefits of DHA treatment depend upon the type of inflammatory particle, magnitude of inflammation, and duration of treatment.
OBJECTIVE AND DESIGN: The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has been reported to suppress inflammation. Pulmonary inflammation can be directly linked to exposure of various occupational and man-made particles leading to pulmonary diseases. Therapeutic treatments are lacking for particle-induced pulmonary inflammation. These studies evaluated DHA as a therapeutic treatment for semi-acute and chronic particle-induced pulmonary inflammation. METHODS: Balb/c mice were oropharyngeal instilled with hydrophobic multi-walled carbon nanotube (MWCNT) or hydrophilic crystalline silica (SiO2) either as one instillation (semi-acute) or once a week for 4 weeks (chronic). One week later, the mice were placed on either a control or 1% DHA-containing diet for 3 weeks (semi-acute) or 12 weeks (chronic). Mice were assessed for inflammatory signaling within the lung lavage fluid, impact on phagolysosomal membrane permeability, shifts of macrophage phenotype gene expression (M1, M2a, M2b, and M2c), and pulmonary histopathology. RESULTS: DHA increased pulmonary inflammatory markers and lung pathology when mice were exposed to SiO2. There were trending decreases of inflammatory markers for MWCNT-exposed mice with DHA treatment, however, mostly not statistically significant. CONCLUSION: The anti-inflammatory benefits of DHA treatment depend upon the type of inflammatory particle, magnitude of inflammation, and duration of treatment.
Authors: Chiu-Wing Lam; John T James; Richard McCluskey; Sivaram Arepalli; Robert L Hunter Journal: Crit Rev Toxicol Date: 2006-03 Impact factor: 5.635
Authors: Nathachit Limjunyawong; John M Craig; H A Daniel Lagassé; Alan L Scott; Wayne Mitzner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-07-31 Impact factor: 5.464
Authors: Melissa A Bates; Christina Brandenberger; Ingeborg I Langohr; Kazuyoshi Kumagai; Adam L Lock; Jack R Harkema; Andrij Holian; James J Pestka Journal: PLoS One Date: 2016-08-11 Impact factor: 3.240